CORRESP Filing
Ernexa Therapeutics Inc.
Date: March 26, 2026 · CIK: 0000748592 · Accession: 0001493152-26-012941
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294307
Letter
Ernexa Therapeutics Inc.
Cambridge Street, Suite 18A
Cambridge, MA 02141
March 26, 2026
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
RE: Ernexa Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-294307
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Requested Date: March 30, 2026
Requested Time: 4:30 pm, Eastern Time
Ladies and Gentlemen:
Ernexa Therapeutics Inc. (the "Company") hereby requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-294307), be accelerated pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it is declared and becomes effective at 4:30 pm Eastern Time on March 30, 2026, or as soon thereafter as possible.
Please contact our counsel, Steven Lipstein of Lucosky Brookman LLP at 732-395-4416 with any questions you may have regarding this request. In addition, the Company requests that you kindly notify Mr. Lipstein by telephone when this request for acceleration has been granted.
Sincerely
yours,
ERNEXA
THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm Ernexa Therapeutics Inc. 1035 Cambridge Street, Suite 18A Cambridge, MA 02141 March 26, 2026 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Ernexa Therapeutics Inc. Registration Statement on Form S-3 File No. 333-294307 REQUEST FOR ACCELERATION OF EFFECTIVENESS Requested Date: March 30, 2026 Requested Time: 4:30 pm, Eastern Time Ladies and Gentlemen: Ernexa Therapeutics Inc. (the "Company") hereby requests that the effective date of the Company's Registration Statement on Form S-3 (File No. 333-294307), be accelerated pursuant to Rule 461 under the Securities Act of 1933, as amended, so that it is declared and becomes effective at 4:30 pm Eastern Time on March 30, 2026, or as soon thereafter as possible. Please contact our counsel, Steven Lipstein of Lucosky Brookman LLP at 732-395-4416 with any questions you may have regarding this request. In addition, the Company requests that you kindly notify Mr. Lipstein by telephone when this request for acceleration has been granted. Sincerely yours, ERNEXA THERAPEUTICS INC. /s/ Sanjeev Luther Sanjeev Luther President, Chief Executive Officer and Director